[LCID Study Number: 20193007]
NRG-GY012: A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women With Recurrent, Persistent or Metastatic Endometrial Cancer
The purpose of this study is to compare any good and bad effects of using experimental study drugs cediranib alone, olaparib alone, or a combination of cediranib and olaparib.
Disease/Condition: Endometrial Cancer, Uterine Cancer
Department: Hematology and Oncology
Status: Active, Not Recruiting
Location(s): Lahey Hospital & Medical Center (Burlington); Lahey Medical Center, Peabody
Primary Contact Email: [email protected]
Primary Contact Phone: 781-744-3421